Drug Trial Radar · NCT04197479
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Last checked: Nov 20, 2026Latest source record: Sep 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,343
Actual
Start
Dec 16, 2019
Primary completion
Jan 6, 2023
Study completion Jan 6, 2023
Sponsor
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo. At least 100 patients will be enrolled in a 100 mg open-label arm and will include a special safety population (eg, patients with compensated NASH cirrhosis).
Conditions
- Non-Alcoholic Fatty Liver Disease
Interventions
PlaceboDrug
Matching tablets
ResmetiromDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the incidence of adverse events.Time frame: 52 weeks
Locations
77 sites in 2 countries. Site status is shown where the registry gives one.
Central Research Associates
Birmingham, Alabama
Arizona Liver Health - Chandler
Chandler, Arizona
East Valley Family Physicians
Chandler, Arizona
The Institute For Liver Health - Glendale
Glendale, Arizona
Arizona - Desert Clinical Research
Mesa, Arizona
The Institute For Liver Health - Tucson
Tucson, Arizona
Adobe Gastroenterology
Tucson, Arizona
Arkansas Gastroenterology
North Little Rock, Arkansas
Fresno Clinical Research Center
Fresno, California
National Research Institute - Huntington Park
Huntington Park, California
Ruane Clinical Research Group
Los Angeles, California
National Research Institute - Los Angeles
Los Angeles, California
Catalina Research Institute
Montclair, California
National Research Institute - Panorama City
Panorama City, California
Alliance Clinical Research
Poway, California
San Fernando Valley Health Institute
West Hills, California
South Denver Gastroenterology - Swedish Medical Center Office
Englewood, Colorado
Excel Medical Clinical Trials
Boca Raton, Florida
Velocity Clinical Research, Hallandale Beach (MD Clinical)
Hallandale, Florida
Floridian Clinical Research
Hialeah, Florida
Nature Coast Clinical Research - Inverness
Inverness, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Florida Research Institute
Lakewood Rch, Florida
Miami Dade Medical Research Institute
Miami, Florida
Orlando Research Center
Orlando, Florida
Progressive Medical Research
Port Orange, Florida
Covenant Research
Sarasota, Florida
The Villages Research Center
The Villages, Florida
Gastrointestinal Specialists of Georgia
Marietta, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Chicago Research Center
Chicago, Illinois
Northwestern Memorial Physicians Group
Chicago, Illinois
Iowa Diabetes Research
West Des Moines, Iowa
Kansas Medical Clinic - Gastroenterology
Topeka, Kansas
L-MARC Research Center
Louisville, Kentucky
Digestive Health Center of Louisiana
Baton Rouge, Louisiana
Tandem Clinical Research - New Orleans Area Site
Marrero, Louisiana
Clinical Trials of America
West Monroe, Louisiana
Huron Gastroenterology
Ypsilanti, Michigan
Gastrointestinal Associates & Endoscopy Center - Flowood
Flowood, Mississippi
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.